首页> 外文期刊>Saudi Pharmaceutical Journal >Phenol as a novel sclerosing agent: A safety and efficacy study on experimental animals
【24h】

Phenol as a novel sclerosing agent: A safety and efficacy study on experimental animals

机译:苯酚作为新型硬化剂:对实验动物的安全性和有效性研究

获取原文
           

摘要

Background: Varicose and ectatic cutaneous vessels are common chronic conditions that might need surgical treatment. There are several treatment modalities, but all can cause complications and have significant recurrence rates. A new effective and safe treatment with low or no recurrence is needed. Phenol seems to be a potential therapeutic agent. Objective: To assess the efficacy and safety of phenol as a sclerosing agent in the treatment of varicose veins and other vascular ectatic conditions. Methods: The dorsal ear veins of white New Zealand rabbits were injected with 0.1ml of a sclerosing agent. Four experimental groups were used to test the sclerosant efficacy of different concentrations of phenol (1%, 5%, 20% and 50%). Sodium tetradecyl sulphate (STS), a commonly used sclerosing agent, was used as a positive control, while normal saline was used as a negative control. The blood vessels of the treated ears were photographed before and 1h, 2days, 8days and 45days after treatment. Biopsies from the treated areas were obtained for histologic examinations. Results: A concentration of 1% phenol was too low to cause significant vascular changes, whereas a concentration of 5% phenol caused 90% lumen narrowing. Interestingly, 1% STS only caused 25% lumen narrowing. Concentrations of 20 and 50% phenol caused 100% lumen narrowing but caused haemorrhage and necrosis. Toxicity monitoring showed no apparent haematologic, cardiac, pulmonary, hepatic or renal toxicity associated with the concentrations of phenol used in this study. Conclusion: A concentration of 5% phenol appears to be a potent and safe sclerosing agent for ectatic small vessels. This provides a significant new therapeutic option, which may eventually advance to the clinic and have an impact on the treatment of patients suffering from varicose veins and other vascular ectatic conditions.
机译:背景:静脉曲张和直肠直肠血管是常见的慢性病,​​可能需要手术治疗。有几种治疗方法,但是所有方法都可能引起并发症,并且复发率很高。需要一种新的有效,安全的治疗方法,以减少或避免复发。苯酚似乎是潜在的治疗剂。目的:评估苯酚作为硬化剂治疗静脉曲张和其他血管扩张状况的有效性和安全性。方法:向新西兰白兔的背耳静脉注射0.1ml硬化剂。四个实验组用于测试不同浓度的苯酚(1%,5%,20%和50%)的硬化剂功效。常用的硬化剂十四烷基硫酸钠(STS)用作阳性对照,而生理盐水用作阴性对照。在治疗前和治疗后1h,2天,8天和45天拍摄被治疗的耳朵的血管。从治疗区域获得活检组织学检查。结果:1%的苯酚浓度太低而无法引起明显的血管变化,而5%的苯酚浓度导致90%的管腔变窄。有趣的是,1%的STS仅导致25%的管腔变窄。浓度为20%和50%的苯酚会导致100%的管腔变窄,但会引起出血和坏死。毒性监测表明,与本研究中使用的苯酚浓度无关,没有明显的血液,心脏,肺,肝或肾毒性。结论:浓度为5%的苯酚似乎是用于直肠小血管的有效和安全的硬化剂。这提供了一种重要的新治疗选择,该选择可能最终会进入临床,并对患有静脉曲张和其他血管扩张状况的患者的治疗产生影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号